Company profile: Avalo Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for immunologic, immuno-oncologic and rare genetic disorders, advancing treatments for rare and orphan diseases. Pipeline includes AVTX-009 (anti-IL-1β) for inflammatory diseases; quisovalimab (anti-LIGHT) for inflammatory conditions; AVTX-008 (BTLA agonist) for immune dysregulation; and AVTX-002 (anti-LIGHT) in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome.
Products and services
- AVTX-002: A fully human monoclonal antibody against human LIGHT (Phase 2) for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome
- AVTX-009: An anti-IL-1β monoclonal antibody targeting inflammatory diseases, part of Cerecor’s clinical-stage pipeline advancing treatments for immunologic disorders
- AVTX-008: A BTLA agonist fusion protein aimed at treating immune dysregulation disorders within rare and orphan disease settings
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avalo Therapeutics
Annovis Bio
HQ: United States
Website
- Description: Provider of treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders, including: Buntanetap, an oral small molecule inhibiting multiple neurotoxic proteins; ANVS405, an IV formulation for acute neurodegeneration like TBI and stroke; and ANVS301, a Phase 1 compound aiming to increase cognitive capabilities in later-stage Alzheimer’s and dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovis Bio company profile →
Freespira
HQ: United States
Website
- Description: Provider of the only FDA-cleared, at-home, drug-free digital therapeutic proven to significantly reduce or eliminate panic attacks, panic disorder, and PTSD symptoms in 28 days. The Freespira treatment uses a sensor and tablet to normalize breathing. Also offers resources for health plans, employees, and individuals, a veterans relief program, and a provider referral program with insurance coverage information.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freespira company profile →
Handl Therapeutics
HQ: Belgium
Website
- Description: Provider of a therapeutics platform to deliver transformative advanced medicines to the market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Handl Therapeutics company profile →
Helius Medical
HQ: United States
Website
- Description: Provider of neurotechnology for neurological wellness, offering PoNS Therapy, a program combining the PoNS device with physical therapy to improve gait and balance deficits in patients with neurological conditions, and the PoNS Device, a non-implantable device delivering mild electrical tongue stimulation to promote neuroplasticity and improve motor function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helius Medical company profile →
Phenox
HQ: Germany
Website
- Description: Provider of neuroradiological and radiological medical devices for treating acute ischemic stroke and intracranial aneurysms, including mechanical thrombectomy devices (pRESET), flow modulation devices (p64), bifurcation aneurysm implants (pCONUS), self-expanding stent systems (pEGASUS), and antithrombogenic HPC coatings that reduce thrombus formation by preventing platelet adhesion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phenox company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avalo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avalo Therapeutics
2.2 - Growth funds investing in similar companies to Avalo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avalo Therapeutics
4.2 - Public trading comparable groups for Avalo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →